Navigation Links
USDM Life Sciences Names Holger Braemer, Vice President of EU and UK Division and Managing Director of USDM Europe GmbH in Germany
Date:4/20/2017

USDM Life Sciences, the leading risk management, technological innovation and business process optimization firm for the life sciences and healthcare industries, is pleased to announce Holger Braemer as Vice President of its Europe division and Managing Director of the new established USDM subsidiary “USDM Europe GmbH” based in Germany.

Braemer is an integral part of USDM’s expansion of services and solutions for medical device and pharmaceutical manufacturers based in the European Union and United Kingdom. He will help USDM’s clients with strategy and identification of technology solutions that will not only help life science companies move faster and more efficiently, but also adhere to strict regulatory requirements that vary across the globe.

One of USDM’s areas of focus will be helping medical device manufacturers comply with the In vitro Diagnostic Medical Devices (IVDR) and Medical Devices (MDR) regulations that were recently approved by the European Union Council.

"We are thrilled with the opportunity to help EU and UK based life science companies with their compliance and technology challenges and goals like we’ve been doing in the United States for the past 18 years,” said Kevin Brown, Managing Partner at USDM Life Sciences. “Holger brings the ideal skills to the table to lead this effort – a strong understanding of the needs of life science organizations and a proven track record of growth and success in the industry.”

“USDM’s DNA is all about the incredible people we have on board. Real experts in the regulated world coming from leading life science companies and regulatory authorities like the FDA. These experts make the difference for our customers and partners and help balance accelerating time to market with regulatory compliance, said Braemer. “I am looking forward to contributing to the major impact USDM has already made on the life science and healthcare industries.”

For more than 15 years, Braemer has worked in the life sciences industry for USDM partners such as PTC, Dassault Systèmes-BIOVIA, Intel-Wind River and Sparta Systems, with a strategic focus on the life sciences vertical including pharmaceutical, biotech, medical devices and healthcare. He successfully helped these organizations develop their Life Sciences verticals in the Central European region. Braemer is based in Germany.

About USDM Life Sciences:
USDM Life Sciences is a global life science and healthcare services company, providing strategy and compliant technology solutions to regulated industries. If you work in Life Sciences or Healthcare, partnering with USDM Life Sciences makes it easy to accelerate innovation and maximize productivity. USDM Life Sciences only focuses on regulated industries and has built trusted partnerships with the most innovative technology companies in the world, and boast a staff of industry leading experts in the areas of technology and compliance.

Read the full story at http://www.prweb.com/releases/2017/04/prweb14236909.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Navitas Life Sciences Augments Global Executive Management Team
2. Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares
3. Intec Pharma Appoints U.S. Life Sciences Executive Jeffrey A. Meckler to its Board of Directors as Vice Chairman
4. EU Adopts New Diagnostics and Medical Device Regulations, USDM Life Sciences Helps Organizations Comply
5. Charm Sciences Announces New Sales/Business Manager
6. Cancer and Immunotherapy Symposium Hosted by ACEA Biosciences Gathers Clinicians and Scientists From Around the World
7. Vinod Shah, PhD, Former Senior Research Scientist in FDA Office of Pharmaceutical Sciences, Joins NDA Partners as Expert Consultant
8. Exact Sciences to host first-quarter 2017 results webcast and call
9. TOMA Biosciences Releases the COMPASS Tumor Profiling System
10. DuPont Pioneer Provides Access to Proprietary Phenotyping Technology; Sponsors Purdue Endowed Chair in Plant Sciences
11. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking ... initiative announced today. The bold new look is part of a transformation to ... into a significant growth period. , It will also expand its service offering from ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):